Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Yunnan Center for Disease Control and Prevention | OTHER |
| Yunnan AIDS Care Center | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to screen the optimal intervention strategies to rapid establish the protective barriers against HIV-infection by maximally decreasing the viremia among HIV- infected patients.
Sexual transmission became the primary route of HIV transmission in China and heterosexual transmission also contributed greatly to HIV epidemic which was mostly reported in South-west rural areas. In past years, Yunnan has experienced powerful campaign of scaling-up the HIV identification as well as antrertroviral therapy.
This study will investigate how to reach the last two of HIV'90-90-90 targets': to provide antiretroviral therapy (ART) for 90% of who diagnosed HIV infection and to achieve viral suppression for 90% of those treated.
The study population consists of participants who received an newly diagnosed HIV infection within the study period. All rerolled participants will be randomized into different study group. In intervention group, medical institutions will provide patients personal involved intervention strategies which guided by frequent viral load detection, and providing of the dosage form of 400 mg EFV in their antiviral therapy.
Main assessment measures are viral suppression rate of HIV-infected patients and treatment coverage .
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| routine care group | No Intervention | Medical institutions will provide patients routine care according to the national program standard. | |
| medicine intervention group | Experimental | The dosage of 400 mg EFV will be used in the antiviral therapy. |
|
| consolidated intervention group | Experimental | Medical institutions will provide personal involved intervention strategies as well as the providing of dosage form of 400 mgEFV in their antiviral therapy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Personal involved intervention strategies | Behavioral | Medical institutions will provide personal involved intervention strategies for patients which guided by viral load testing monthly until viral load drop below the detection limit. |
| Measure | Description | Time Frame |
|---|---|---|
| Viral suppression of HIV-infected patients | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Treatment coverage | 12 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Zhao Yan, PHD | Contact | +86-10-5338-0980 | zhaoyan@chinaaids.cn |
| Name | Affiliation | Role |
|---|---|---|
| Zhao Yan, PHD | National Center for AIDS/STD Control and Prevention | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lincang Center for Disease Control and Prevention | Lincang | Yunnan | China | |||
| Wenshan Center for Disease Control and Prevention |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42332571 | Derived | Gao L, Chang W, Shu Y, Liu Y, Zhang M, Yang Q, Li J, Pai H, Huang L, Chen Y, Yang Z, Lu F, Dong X, Feng Y, Xia X. Emergence of two novel HIV-1 Circulating Recombinant Forms (CRF190_0708 and CRF191_0708): molecular characterization and clinical insights from a five-year study in Yunnan, China. BMC Microbiol. 2026 Jun 23. doi: 10.1186/s12866-026-05323-x. Online ahead of print. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C098320 | efavirenz |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| The dosage of 400mg EFV | Drug | The dosage of 400mg EFV will be used in the antiviral therapy. |
|
| Wenshan |
| Yunnan |
| China |